Patents by Inventor Wancheng Guo

Wancheng Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH-PURITY THIENOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20240317773
    Abstract: A thienopyrimidine compound (a compound of formula N) and a preparation method therefor are provided. Specifically, the preparation method includes the steps of: (a) in a solvent A, reacting, in the presence of an organic base and acyl chloride, a compound of formula N-2 with 3-amino-6-methoxypyridazine to obtain a compound of formula N-1; and (b) in a solvent B, converting, in the presence of a base, the compound of formula N-1 into the compound of formula N. The preparation method does not require toxic and expensive reagents, has mild reaction conditions and a high product purity, and is suitable for industrial production.
    Type: Application
    Filed: September 6, 2021
    Publication date: September 26, 2024
    Inventors: Wancheng GUO, Fuchang ZHANG, Yongli DUAN, Xiongpeng DUAN, Guoping WANG
  • Crystalline forms of Acalabrutinib
    Patent number: 11345706
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 31, 2022
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Crystalline Forms of Acalabrutinib
    Publication number: 20210130360
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Application
    Filed: August 23, 2018
    Publication date: May 6, 2021
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Processes for the preparation of Ribociclib and intermediates thereof
    Patent number: 10723739
    Abstract: The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribociclib (1).
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 28, 2020
    Assignee: Apotex Inc.
    Inventors: Daoke Dou, Kangying Li, Fuchang Zhang, Jiang Pei, Wancheng Guo
  • Processes for the Preparation of Ribociclib and Intermediates Thereof
    Publication number: 20190345163
    Abstract: The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribociclib (1).
    Type: Application
    Filed: May 13, 2019
    Publication date: November 14, 2019
    Inventors: Daoke Dou, Kangying Li, Fuchang Zhang, Jiang Pei, Wancheng Guo